Volume 5.23 | Jun 27

Prostate Cell News 5.23 June 27, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Remodeling of Channel-Forming ORAI Proteins Determines an Oncogenic Switch in Prostate Cancer
By mimicking ORAI protein remodeling observed in primary tumors, scientists demonstrate in in vitro models that enhanced ORAI3 expression favors heteromerization with ORAI1 to form a novel channel. [Cancer Cell] Abstract | Graphical Abstract
ProstaCult: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

TRIB1 Supports Prostate Tumorigenesis and Tumor-Propagating Cell Survival by Regulation of Endoplasmic Reticulum Chaperone Expression
Researchers applied a functional genomic approach to the three-dimensional spheroid cell culture model and identified TRIB1, a member of the Trib family of serine/threonine kinase-like proteins, as an essential factor for prostate cancer cell growth and survival. [Cancer Res] Abstract

miR-409-3p/-5p Promotes Tumorigenesis, Epithelial to Mesenchymal Transition and Bone Metastasis of Human Prostate Cancer
Elevated expression of miR-409-3p/-5p was observed in bone metastatic prostate cancer cell lines and human prostate cancer tissues with higher Gleason scores. [Clin Cancer Res] Abstract

Enhanced Enrichment of Prostate Cancer Stem-Like Cells with Miniaturized 3D Culture in Liquid Core-Hydrogel Shell Microcapsules
It usually takes approximately 10 days for the widely used conventional approach to enrich cancer stem-like cells (CSCs) through the formation of CSC-containing aggregates. Scientists report the time can be shortened to two days while obtaining prostate CSC-containing aggregates with better quality based on the expression of surface receptor markers, dye exclusion, gene and protein expression, and in vivo tumorigenicity. [Biomaterials] Abstract

Prostate Cancer Cells Preferentially Home to Osteoblast-Rich Areas in the Early Stages of Bone Metastasis – Evidence from In Vivo Models
Researchers mapped the distribution of three human prostate cancer cell lines (PC3-NW1, LN-CaP, and C4 2B4) colonizing the tibias of athymic mice following intracardiac injection and evaluated their interaction with potential metastatic niches. [J Bone Miner Res] Abstract

Chemical Proteomics Identifies Heterogeneous Nuclear Ribonucleoprotein (hnRNP) A1 as the Molecular Target of Quercetin in Its Anti-Cancer Effects in PC-3 Cells
Scientists identified hnRNPA1 as a direct target of quercetin. hnRNPA1 was recruited to stress granules after treatment of cells with quercetin for up to 48 hours, and the levels of cellular inhibitor of apoptosis, an IRES-translation dependent protein, were reduced by hnRNPA1 regulation. [J Biol Chem] Abstract | Full Article

A Claudin 3 and Claudin 4-Targeted Clostridium perfringens Protoxin Is Selectively Cytotoxic to PSA-Producing Prostate Cancer Cells
A modified protoxin was constructed with a tethered ligand attached to the C-terminus connected by a flexible linker containing a PSA-specific protease cleavage site. This engineered protoxin selectively and efficiently lyses PSA-producing prostate cancer cells whereas CLDN3 and CLDN4 positive cells that do not express PSA are resistant to cytolysis. [Cancer Lett] Abstract

DNA Aptamer Evolved by Cell-SELEX for Recognition of Prostate Cancer
Researchers developed a new aptamer probe Wy-5a against prostate cancer (PCa) cell line PC-3 by cell-SELEX (Systematic Evolution of Ligands by Exponential enrichment) technique. Wy-5a shows high specificity to the target cells with dissociation constants in the nanomolar range, and does not recognize other tested PCa cell lines and other tested tumor cell lines. [PLoS One] Full Article

EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer
Scientists showed that interferon-γ receptor 1 is directly repressed by EZH2 in a MYC-dependent manner and is downregulated in a subset of metastatic prostate cancers. [Cell Rep] Full Article | Graphical Abstract


Temporal Patterns of Late Bowel and Bladder Radiotherapy Toxicity in a Randomized Controlled Trial Assessing Duration of Neo-Adjuvant Hormones in Prostate Cancer
Researchers assessed the temporal patterns of late gastrointestinal and genitourinary radiotherapy toxicity and resolution rates in a randomized controlled trial assessing duration of neo-adjuvant hormone therapy for localized prostate cancer. [Acta Oncol] Abstract

Time to Disease-Related Pain and First Opioid Use in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Sipuleucel-T
Researchers examined the effect of sipuleucel-T on time to disease-related pain and time to first use of opioid analgesics in metastatic castration-resistant prostate cancer (mCRPC) using data pooled from three randomized Phase III studies in men with asymptomatic or minimally symptomatic mCRPC. [Prostate Cancer Prostatic Dis] Abstract

[Free On-Demand Webinar] Detect Cancer Stem Cells with ALDEFLUOR - Watch Now.
The Role of MicroRNA in Castration-Resistant Prostate Cancer
The authors discuss the robustness of microRNAs (miRNAs) as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with castration-resistant prostate cancer. [Urol Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Madison Vaccines Incorporated Announces Expansion of a Phase II Clinical Trial for MVI-816, Its Lead DNA Vaccine for Prostate Cancer
Madison Vaccines Incorporated announced enrollment has begun in the expansion of a Phase II clinical trial of its lead product candidate MVI-816. [Madison Vaccines Incorporated] Press Release

Chesapeake Urology Associates Presents Significant Financial Gift to Urology Care Foundation in Support of Critical Prostate Cancer Research
In ongoing support of prostate cancer research, Sanford Siegel, M.D., President and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with a check for $114,248 in support of its prostate cancer research efforts. [Chesapeake Urology Associates (PR Newswire Association LLC)] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW EMBO | EMBL Symposium: Epithelia: The Building Blocks of Multicellularity
August 27-30, 2014
Heidelberg, Germany

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

NEW Postdoctoral Fellow – Prostate Cancer Research (Tulane University Health Sciences Center)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Postdoctoral Position – Role of Chromatin in Prostate Cancer (University of Victoria)

Postdoctoral Position – Prostate Cancer Aggressiveness and Progression in Prostate Cancer (Roswell Park Cancer Institute)

PhD Studentship – Prostate Cancer Research (Cardiff University)

Postdoctoral Fellow – Prostate Cancer Research (Henry Ford Hospital)

Research Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Associate – Prostate Cancer Research (Medical University of South Carolina)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development: High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us